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Abstract We have examined the potential role of MAP kinase 
in the regulation of endothelial cell PGI2 synthesis, vWF 
secretion and E-selectin expression using the specific MEK 
inhibitor PD98059. PD98059 dose-dependently attenuated the 
tyrosine phosphorylation and activation of !}42 mapk in response to 
thrombin or inflammatory cytokines. Inhibition of thrombin- 
mapk induced p42 activation was paralleled by an inhibitory effect 
of PD98059 on thrombin-driven PGI2 generation but not on vWF 
secretion or IL-lo0TNF~-induced E-selectin expression. These 
results provide evidence for a key role for !142 mapk in the acute 
regulation of PGI2 synthesis in human endothelial cells and 
suggest that activation of the MAP kinase cascade is not 
obligatory for cytokine-stimulated E-selectin expression. 
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1. Introduction 
Endothelial cells play a major role in regulating vascular 
homeostasis by modulating the secretion or surface expression 
of local mediators in response to diverse physiological stimuli 
[1]. Our recent studies in human umbilical vein endothelial 
cells (HUVEC) have implicated tyrosine kinases as regulators 
of (i) the rapid synthesis and release of prostacyclin (PGI2) in 
response to G protein-coupled agonists (GPCA) [2], and (ii) 
the expression of leucocyte adhesion molecules following ex- 
posure to inflammatory cytokines [3]. Thus, we have shown 
that thrombin, histamine or cytokines promote changes in the 
phosphotyrosine content of endogenous HUVEC proteins 
and that inhibitors of tyrosine kinases can attenuate distinct 
agonist-induced tyrosine phosphorylation events in parallel 
with PGIz release [2] or adhesion molecule expression [3]. 
One of the major tyrosine phosphorylated proteins observed 
in GPCA-  [2] or cytokine-stimulated HUVEC [4] corre- 
sponds to the 42 kDa form of MAP kinase (p42 mapk) which 
is activated by phosphorylation on tyrosine and threonine 
residues catalysed by an upstream, dual-specificity MAP ki- 
nase kinase (MEK) [5]. In addition, there is a strong correla- 
tion between agonist-induced p42 mapk activation and some of 
the functional responses of HUVEC and we have hypothe- 
sised that activation of the MAP kinase cascade may be nec- 
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essary both for GPCA-driven PGI2 synthesis [2], and for cy- 
tokine-induced adhesion molecule expression by human 
endothelium [4]. 
In the present study we have employed a highly specific, 
non-competitive inhibitor of MEK (PD98059 [6-8]) to address 
directly the role of p42 mapk in thrombin-induced PGI2 genera- 
tion and in E-selectin expression evoked by I L - la  or TNFa .  
2. Materials and methods 
2.1. Materials 
125I-labelled 6-keto PGFla was purchased from Metachem Diag- 
nostics Ltd., Piddington, Northampton, UK. Histamine dihydrochlor- 
ide, human ~-thrombin and bovine serum albumin (BSA; fraction V) 
were from Sigma (Poole, Dorset, UK). The monoclonal anti-p44 m~pk 
antibody (which cross-reacts with p42 mapk) and the polyclonal anti- 
phosphotyrosine antibody were from Affiniti Research Products Ltd., 
Nottingham, UK. Horseradish peroxidase conjugated goat anti-rabbit 
and rabbit anti-mouse immunoglobulins were purchased from Pierce 
and Warriner (Chester, Cheshire, UK.). Human recombinant IL-la 
and TNFa, and monoclonal anti-E-selectin antibody were from R&D 
Systems Ltd. (Oxford, UK). Reagents for SDS-PAGE were from 
National Diagnostics (Hessle, Hull, UK). Enhanced chemilumines- 
cence (ECL) Western Blot detection reagent and Hyperfilm-ECL 
film were obtained from Amersham Int., Bucks, UK. Culture media 
were from Sigma or Life Technologies (Paisley, UK). PD98059 was 
kindly provided by Dr. A. Saltiel, Parke-Davis, MI, USA. Mouse 
monoclonal anti-von Willebrand Factor (vWF) antibody 
(CLBRAg35) was a gift from Dr. J.A. Van Mourik (Central Blood 
Laboratory, Amsterdam, The Netherlands). All other reagents were 
obtained from Sigma or BDH (Poole, Dorset, UK) at the equivalent 
of AnalaR grade. 
2.2. Cell culture 
Human umbilical vein endothelial cells (HUVEC) were isolated and 
cultured as previously described [2]. Experiments were performed on 
HUVEC passaged twice from primary cultures; cells were used 4-5 
days after seeding at confluent density onto the appropropriate issue 
culture plasticware precoated with 1% (w/v) gelatin. 
2.3. Immunoblotting 
Confluent HUVEC in 60 mm dishes (approx 1 X 106 cells/dish) were 
serum-deprived for 12-16 h in M199 containing 5 mM glutamine 
(M199G). Monolayers were washed twice with Krebs-Ringer bicarbo- 
nate buffer (118 mM NaC1, 4.75 mM KC1, 1.2 mM MgCI2, 1.0 mM 
CaC12, 25 mM NaHCO3, pH 7.4, 37°C), and subsequently challenged 
with agonist. In some experiments a portion of the cell supernatant 
was retained for measurement of 6-keto PGFla content. For experi- 
ments employing cytokines, incubations were carried out in M199G. 
Incubations were terminated and whole cell lysates prepared as pre- 
viously described [2]. Proteins were resolved by SDS-PAGE (10%) and 
transferred onto PVDF (Immobilon-P T) membrane (Millipore, Bed- 
ford, MA). Membranes were blocked for 3 h in TBST (50 mM Tris, 
150 mM NaC1, 0.02% (v/v) Tween 20, pH 7.4) containing 3% (w/v) 
BSA and probed with anti-phosphotyrosine or anti-p441p42 m~pk anti- 
body (diluted in TBST/0.2% (w/v) BSA). Blots were washed in TBST 
(6× 10 min) and subsequently incubated (1 h) in TBST/0.2% BSA 
containing HRP-conjugated goat anti-rabbit or anti-mouse IgG as 
appropriate. Immunoreactive proteins were visualised using ECLac- 
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cording to the manufacturer's instructions. Where indicated blots 
were stripped by incubation (50°C, 30 min) in a buffer comprised of 
62.5 mM Tris-HC1 (pH 6.7), 2% (w/v) SDS and 0.7% (v/v) B-mercap- 
toethanol and reprobed following extensive washing in TBST. 
2.4. Measurement of PGI2 release and vWF secretion 
Confluent cultures of HUVEC in 24-well tissue culture trays were 
washed twice in serum-free Dulbecco's Modified Eagles Medium 
(DMEM; pH 7.4) containing 20 mM HEPES. Cell monolayers were 
then exposed to agonist in the absence or presence of PD98059 or 
vehicle alone. The supernatant fraction was sampled following a 60 
min exposure to agonist and assayed for 6-keto PGFI= (the stable 
breakdown product of PGI2) and vWF using, respectively, radioim- 
munoassay and enzyme-linked immunosorbent assay procedures as 
previously described [2]. Supernatants from quiescent HUVEC mono- 
layers used in the immunoblotting studies were also assayed routinely 
for 6-keto PGFI= content; vWF secretion could not be accurately 
assessed in these cells due to the inhibitory effects of serum depriva- 
tion on cellular vWF content [9]. 
2.5. Measurement of E-selectin expression 
Confluent monolayers of HUVEC in 96-well tissue culture trays 
were exposed to PD98059 for 30 min prior to incubation with cyto- 
kine for 4 h in the continued presence of inhibitor. Agonist-induced 
expression ofE-selectin was then assessed by enzyme-linked immuno- 
sorbent assay [3]. 
2.6. Statistics 
Statistical nalysis was performed using the Peritz F multiple means 
comparison test. P < 0.05 was considered statistically significant. 
3. Resu l ts  
3.1. PD98059 inhibits phosphorylation and activation 
o f  p42 mapk in response to thrombin 
Our previous tudies in HUVEC have shown that thrombin 
and histamine promote the rapid tyrosine phosphorylation f 
a 42 kDa protein and have demonstrated using 'mobility-shift' 
and specific in vitro kinase assays that this protein corre- 
sponds to the activated form of p42 mapk [2,10-12]. The effects 
of a 30 min preincubation with PD98059 (5-50 p.M) on the 
tyrosine phosphorylation profile and on the electrophoretic 
mobility shift of p42 mapk observed following thrombin stimu- 
lation of quiescent HUVEC are shown in Fig. 1. The upper, 
slower migrating form of p42 mapk in Fig. 1B corresponds to 
the 42 kDa tyrosine phosphorylated protein in Fig. 1A. After 
a 1 min incubation, thrombin marginally enhanced the phos- 
phorylation state of p42 mapk and strongly increased phosphor- 
ylation of a protein migrating at approx. 95 kDa (p95), in 
addition to affecting the phosphorylation of a number of 
other proteins (-~60-70 kDa, ~100-130 kDa; Fig. 1A, 
lane 2). Following 10 min exposure to thrombin (Fig. 1A, 
lane 8) there was a greater phosphorylation of p42 mapk, a 
delayed increase in phosphotyrosine content of proteins ap- 
proximating 90 and 65-75 kDa, and no detectable phosphor- 
ylation of p95. A protein of approx. 44 kDa was also tyrosine 
phosphorylated in the presence of thrombin (Fig. 1A, lane 8). 
The level of p42 mapk phosphorylation bserved in the ab- 
sence of agonist varied between experiments (compare Fig. 1, 
lane 1 with Fig. 2, lane 1) and this basal activation could be 
reduced by removal of extracellular calcium or by exposure to 
the protein tyrosine kinase inhibitor genistein ([2] and data 
not shown). PD98059 (50 ~tM) abolished basal p42 mapk phos- 
phorylation and at 5 I.tM reduced agonist-stimulated 1342 rnapk 
activation to a level equal to or below that observed in control 
cells (Fig. 1A,B). PD98059 also inhibited p42 mapk activation 
following challenge with either histamine (1 p.M) or the tyr- 
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Fig. 1. PD98059 inhibits basal and thrombin-induced tyrosine phos- 
phorylation and activation of p42 mapk. Confluent HUVEC in P60 
tissue-culture dishes were serum-starved for 16 h in M199G. 
Washed monolayers were exposed to various concentrations of
PD98059 (or to 0.001% DMSO) for 30 min and then challenged 
with thrombin (1.0 U/ml) in the continued presence of inhibitor. In- 
cubations were terminated after 1 or 10 min exposure to agonist, 
lysed and subjected to SDS-PAGE followed by immunoblotting. (A) 
Blot was probed with anti-phosphotyrosine a tibody and immuno- 
reative proteins visualised using ECL. (B) The blot in A was 
stripped and reprobed with anti-MAP kinase antibody followed by 
ECL development. Data are from a representative experiment from 
a series of 3. Values for release of PGI2 (6-keto PGFla; ng/well) 
from HUVEC in each well are also shown. 
osine phosphatase inhibitor pervanadate (1-50 JaM; data not 
shown). 
PD98059 had no effect on the rapid thrombin-induced 
phosphorylation f p95 (Fig. 1A, lanes 2-5) but reduced the 
thrombin-stimulated tyrosine phosphorylation of p90 and 
p65-75 with maximal inhibition achieved at 25 ~tM (Fig. 
1A, lanes 8-11). The thrombin-induced phosphorylation of
p44 (Fig. 1A, lane 8), which was not observed in control cells, 
was also inhibited in cells pretreated with PD98059 (Fig. 1A, 
lane 9). 
3.2. PD98059 inhibits PGI2 release but not vWF secretion 
To determine whether abolition of p42 inapt activity was as- 
sociated with loss of secretory responsiveness, we examined 
the effects of PD98059 on thrombin- and histamine-induced 
PGI2 release and vWF secretion (Table 1). PD98059 dose- 
dependently attenuated both basal and agonist-stimulated 
PGIz generation with maximal inhibition achieved at 20 
ktM. Comparable ffects of PD98059 on PGI2 synthesis were 
also observed in quiescent HUVEC (see Fig. 1) although the 
extent of both basal and agonist-driven release was greater 
than in cells maintained in serum-containing medium (data 
not shown). In contrast, neither basal nor agonist-driven 
vWF secretion was modified by a 30 min pre-exposure to 
PD98059 (Table 1). Similarly, PD98059 inhibited pervana- 
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date-induced PGI2 release but not vWF secretion (data not 
shown). 
3.3. PD98059 inhibits cytokine-mediated activation o f  p42 m`~pk 
but not E-selectin expression 
Preincubation with PD98059 (5-50 gM) completely blocked 
the phosphorylation of p42 m~pk induced by maximally effec- 
tive concentrations of IL-lc~ (100 U/ml; Fig. 2) or TNFa  
(data not shown). Under the same conditions, however, E- 
selectin expression induced by either cytokine was unaffected 
by pre-exposure to PD98059 at concentrations up to 50 p.M 
(Table 2). 
4. Discussion 
p42 mapk is thought to represent a point of convergence tbr 
mitogenic signals originating from several classes of cell sur- 
face receptor including the receptor tyrosine kinases and those 
that couple to heterotrimeric G proteins [13]. Growing evi- 
dence from a number of cell types, including terminally differ- 
entiated cells, additionally implicates p42 m~pk in the control of 
acute responses to receptor stimulation such as exocytosis and 
arachidonic acid release [14,15]. In endothelial cells p42 mapk 
can be activated by growth factors [16], GPCA [17,18], shear 
stress [19,20] or inflammatory cytokines (this study) but the 
functional relevance of  stimulus-induced changes in p42 mapk 
remains to be determined. In the present study we used a 
novel inhibitor of MEK to explore the potential involvement 
of p42 mapk in thrombin-driven PGI2 synthesis and in cytokine- 
induced expression of E-selectin. At a concentration (5 ]aM) 
previously reported to abolish insulin- or NGF-stimulated 
Table 1 
Effects of PD98059 on PGI2 release and vWF secretion from resting 
and agonist-stimulated HUVEC 
Treatment 6-Keto PGFI~ vWF (mU/ml) 
(pg/well) 
None 39 + 12 4.0 + 0.3 
5 I.tM PD 15+6 a 2.8+0.3 
20 IxM PD < 3 3.1 + 0.2 
50 IxM PD < 3 3.6 + 0.4 
Histamine 1845 + 65 10.4 + 1.7 
His + 5 gM PD 204+6F 10.2+0.3 
His + 20 I.tM PD 19+ 1 c 10.4+ 1.4 
His + 50 I-tM PD < 3 11.0 + 0.2 
None 16 + 3 0.5 + 0.1 
5 I.tM PD 7+2 a 0.7+0.2 
20 gM PD 5+ 1 b 0.6+0.1 
50 liM PD 5 + 2 c 0.6 + 0.2 
Thrombin 81 +_ 6 6.4 + 0.2 
Thr + 5 IxM PD 35+-2 c 5.1 +0.6 
Thr + 20 gM PD 6 + 1 c 3.9 + 1.4 
Thr + 50 IsM PD 4+1 c 6.4+1.8 
Confluent HUVEC monolayers were exposed to the indicated concen- 
trations of PD98059 (PD) or vehicle (0.001% DMSO) for 30 min prior 
to incubation with thrombin (Thr; 1.0 U/ml) or histamine (His; 1 ~tM) 
in the continued presence (or absence) of inhibitor. Cell supernatants 
were sampled after 60 min and assayed for 6-keto PGFla and vWF. 
Data shown are from two representative experiments (one with each 
agonist) from a series of three with each agonist and are given as 
mean+ S.E.M. with quadruplicate determinations per observation. 
< 3 = below assay detection limit. 
ap<0.05 ' bp <0.01, °P <0.001 versus control. 
................................. ~ . . . . . .  ~ ~- 42 kDa 
IL-I~ - + + + + 
PD98059 t~M - 5 25 50 50 
Thrombin - + + 
Fig. 2. Effects of PD98059 on IL-lc~-induced phosphorylation of 
p42 m~pk. HUVEC in P60 dishes were serum-starved for 16 h in 
M199G, washed, and incubated in M199G containing PD98059 
(PD; 5-50 p.M) or vehicle (0.001% DMSO) for 30 min. Cells were 
then exposed to IL-lct (100 U/ml, 30 min) or thrombin (Thr; 1.0 
U/ml, 10 min) in the presence (or absence) of PD and cell lysates 
prepared as described in Section 2. The figure shows an anti-MAP 
kinase immunoblot developed using ECL. Results are representative 
of two similar experiments. 
MAP kinase activation in adipocytes [7] or PC12 cells [21], 
respectively, PD98059 blocked activation of p42 mapk following 
treatment with thrombin, histamine, inflammatory cytokines 
or pervanadate. In agreement with previously published re- 
ports [6] the degree of inhibition depended upon the strength 
of p42 mapk activation; thus, 5 p~M PD98059 abolished p42 m~pk 
activation induced by maximally effective doses of thrombin, 
histamine, or IL-lc¢ whereas 10-fold higher concentrations 
were required to suppress activation induced by pervanadate 
(not shown) which promotes a near complete shift of p42 mapk 
to its phosphorylated, active form. These results provide evi- 
dence for the effectiveness of PD98059 as an inhibitor of 
MEK,  and hence p42 TM,  in human endothelial cells exposed 
to activators of the 'classical' MAP kinase cascade. We also 
observed marginal tyrosine phosphorylation of a =44 kDa 
protein in thrombin-stimulated cells which was also inhibited 
by PD98059. This protein may well correspond to p44 mapk 
which is known to be activated in response to thrombin in 
other cell types, including smooth muscle [22]; inhibition by 
PD98059 would be consistent with previous observations that 
PD98059 totally blocks all measurable in vitro MAP kinase 
activity in adipocytes [8]. However, unlike the phosphoryla- 
tion of the 42 kDa protein (p42m~pk), tyrosine phosphoryla- 
tion of the 44 kDa substrate was not consistently observed in 
our experiments and, if present, (Fig. 1) was clearly only mar- 
ginally phosphorylated compared to p42. The MAP kinase 
antibody used in the present studies is raised against human 
p44 mapk but cross-reacts with p42 mapk. Our previous studies in 
HUVEC [2], and those of others in a HUVEC-derived cell line 
[17], indicate that this antibody does not detect a 44 kDa 
MAP kinase in human endothelial cells, but does so readily 
in bovine endothelial cells (BEC) [17] and human smooth 
muscle cells (R.A. Houliston et al., unpublished). Moreover, 
in BECs p44mapk is not activated under conditions which 
maximally activate p42 mapk [17] whereas both isoforms are 
activated in human smooth muscle. These findings suggest 
that p42 mapk is the major regulated form of MAP kinase in 
human endothelial cells. 
In the present study PD98059 had differential effects on 
thrombin-stimulated tyrosine phosphorylation depending 
upon the time of exposure to agonist. For example, after a 
10 min thrombin challenge, the inhibition of p42 mapk phos- 
phorylation was accompanied by reduced tyrosine phosphor- 
ylation of several higher molecular weight proteins. Given the 
exquisite specificity of PD98059 [6] these effects are unlikely to 
result from direct modulation of other kinases and presum- 
ably reflect phosphorylation events occuring downstream of 
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Table 2 
PD98059 does not affect cytokine-induced xpression of E-selectin 
Treatment E-selectin expression 
(% cytokine stimulated) 
None 5 + 2 
IL-1 99_+5 
IL-1 + 5 ktM PD 99+3 
IL-I + 25 ktM PD 101 +4 
IL-1 + 50 ktM PD 96+4 
None 4 + 2 
TNF~ 100 + 4 
TNFct + 5 ~tM PD 98 _+ 3 
TNFct + 25 txM PD 99 + 3 
TNFa + 50 ktM PD 104 + 3 
HUVEC monolayers in96-well trays were pre-incubated for 30 min in 
M199 containing the indicated concentrations of PD98059 (PD) or 
DMSO vehicle (0.001%). Cells were then challenged with either IL-la 
(100 U/ml) or TNFa (100 U/ml) for a further 4 h in the continued 
presence or absence of PD and E-selectin expression measured by 
ELISA. Data are given as a percentage of the expression evoked by 
cytokine alone (100%) and are mean _+ S.E.M. from 4 separate x- 
periments with triplicate determinations per observation. 
p42 mapk. In contrast, the rapid and prominent thrombin-in- 
duced phosphorylation f a ~ 97 kDa protein was unaffected 
by exposure to PD98059 suggesting that this results from 
kinase activity situated upstream from p42 mapk or in a parallel 
MAP kinase-independent pathway. 
We have previously found that serum-deprived HUVEC 
exhibit enhanced basal and agonist-induced PGI2 synthesis 
compared to cells maintained in serum-containing medium 
(C.P.D. Wheeler-Jones et al., unpublished). This is correlated 
with a more prominent basal and agonist-stimulated phos- 
phorylation of p42 mapk, providing circumstantial evidence 
for a link between PGI2 release and p42 mapk activation. In 
the present study, inhibition of basal and agonist-induced 
p42 m~pk activation by PD98059 was accompanied by a parallel 
inhibition of PGI2 release in both 'resting' and stimulated 
HUVEC. Our ability to detect both p42 m~pk activation and 
PGI2 release in the absence of agonist is not unexpected; 
replacement of medium above endothelial cell monolayers 
subjects the cells to shear stress which is known to promote 
PGI2 release [23] and to enhance phosphorylation a d activa- 
tion of p42 m~pk [19,20]. Taken together these results demon- 
strate a central role for p42 m~pk in the control of PGI2 synth- 
esis/release in HUVEC. Although we cannot exclude the 
potential involvement of a p44 mapk in this response, our in- 
ability to detect basal phosphorylation f p44 together with 
the minor, and delayed thrombin-induced p44 phosphoryla- 
tion, suggests that PGI~ synthesis in human endothelium is
regulated mainly by p42 mapk. In contrast, under conditions 
where thrombin-driven PGI2 release and p42 m~pk activation 
were abolished, PD98059 had no effect on vWF secretion 
suggesting that activation of the MAP kinase cascade is not 
essential for regulated exocytosis in endothelial cells. 
Inflammatory cytokines are known to activate a number of 
parallel kinase cascades in a variety of cell types [24]. In vitro 
studies have shown that one of the downstream targets of 
p42 mapk is the transcription factor ATF-2 [25], the activation 
of which is required for cytokine-induced E-selectin expres- 
sion [26]. However, at concentrations which effectively 
blocked IL-lct- and TNFa-induced p42 m~pk activation, 
PD98059 had no detectable ffect on cytokine-stimulated E- 
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selectin expression. The significance of the MAP kinase cas- 
cade for cytokine-mediated ffects in endothelium remains 
unclear but the present study suggests that activation of 
p42 mapk is not obligatory for expression of E-selectin. 
In summary, we have shown that inhibition of the MAP 
kinase pathway selectively blocks PGI2 release in response to 
G protein-coupled agonists, results which are consistent with 
a key role for p42 mapk in the acute regulation of PGI2 synth- 
esis in human endothelial cells. Further studies are required to 
determine whether this results from p42mapk-mediated phos- 
phorylation of cytosolic phospholipase A2 [16,27]. 
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